amoxicillin and clavulanate potassium

FDA Drug Profile — AUGMENTIN ES-600, AMOXICILLIN AND CLAVULANATE POTASSIUM, amoxicillin and clavulanate potassium, Amoxicillin and Clavulanate Potassium

amoxicillin and clavulanate potassium is listed in the FDA National Drug Code directory with 41 NDC codes, marketed under brand names including AUGMENTIN ES-600, AMOXICILLIN AND CLAVULANATE POTASSIUM, amoxicillin and clavulanate potassium. Available dosage forms: for suspension, tablet, coated, powder, for suspension, tablet, tablet, chewable.

Drug details

Generic Name
amoxicillin and clavulanate potassium
Brand Names
AUGMENTIN ES-600, AMOXICILLIN AND CLAVULANATE POTASSIUM, amoxicillin and clavulanate potassium, Amoxicillin and Clavulanate Potassium
Application Number
NDA050755
Sponsor
USAntibiotics, LLC
NDC Codes
41
Dosage Forms
FOR SUSPENSION, TABLET, COATED, POWDER, FOR SUSPENSION, TABLET, TABLET, CHEWABLE, TABLET, FILM COATED, TABLET, FILM COATED, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
AMOXICILLIN, CLAVULANATE POTASSIUM, AMOXICILLIN SODIUM

Indications and Usage

1 INDICATIONS AND USAGE Amoxicillin and clavulanate potassium tablets are a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta-lactamase inhibitor, indicated for the treatment of infections caused by designated susceptible (confirmed or suspected) beta-lactamase-producing microorganisms ( 1 ): Lower Respiratory Tract Infections ( 1.1 ) Amoxicillin and clavulanate potassium tablets: adults and pediatric patients weighing 40 kg or more Acute Bacterial Sinusitis ( 1.3 ) Amoxicillin and clavulanate potassium tablets: adults and pediatric patients weighing 40 kg or more Acute Bacterial Otitis Media ( 1.4 ) Amoxicillin and clavulanate potassium tablets: adults and pediatric patients weighing 40 kg or more Skin and Skin Structure Infections ( 1.6 ) Amoxicillin and clavulanate potassium tablets: adults and pediatric patients weighing 40 kg or more Urinary Tract Infections ( 1.7 ) Amoxicillin and clavulanate potassium tablets: adults and pediatric patients weighing 40 kg or more Limitations of Use ( 1.8 ) Therapy may be initiated before bacteriological results are available when beta-lactamase-producing pathogens are suspected. When results show susceptibility to amoxicillin alone, amoxicillin and clavulanate potassium tablets should not be used. Usage to Reduce Development of Drug-Resistant Bacteria ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets and other antibacterial drugs, amoxicillin and clavulanate potassium tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Lower Respiratory Tract Infections Amoxicillin and clavulanate potassium tablets are indicated for the treatment of lower respiratory tract infection due to confirmed or suspected beta-lactamase producing Haemophilus influenzae and Moraxella catarrhalis as follows [see Clinical Pharmacology (12.4) , Clinical Studies (14.1) ] : Amoxicillin and Clavulanate Potassium Tablets: adults and pediatric patients weighing greater than or equal to 40 kg 1.3 Acute Bacterial Sinusitis Amoxicillin and clavulanate potassium tablets are indicated for the treatment of acute bacterial sinusitis due to confirmed or suspected beta-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis as follows [see Clinical Pharmacology (12.4) , Clinical Studies (14.4)]: Amoxicillin and Clavulanate Potassium Tablets: adults and pediatric patients weighing greater than or equal to 40 kg 1.4 Acute Bacterial Otitis Media Amoxicillin and clavulanate potassium tablets are indicated for the treatment of acute bacterial otitis media due to confirmed or suspected beta-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis as follows [see Use in Specific Populations (8.4) , Clinical Studies (14.5)] : Amoxicillin and Clavulanate Potassium Tablets: adults and pediatric patients weighing greater than or equal to 40 kg 1.6 Skin and Skin Structure Infections Amoxicillin and clavulanate potassium tablets are indicated for the treatment of skin and skin structure infections due to confirmed or suspected beta-lactamase-producing S. aureus , Escherichia coli , and Klebsiella species as follows [see Use in Specific Populations (8.4) ] : Amoxicillin and Clavulanate Potassium Tablets: adults and pediatric patients weighing greater than or equal to 40 kg 1.7 Urinary Tract Infections Amoxicillin and clavulanate potassium tablets are indicated for the treatment of urinary tract infections due to confirmed or suspected beta-lactamase-producing E. coli , Klebsiella species, and Enterobacter species as follows [see Use in Specific Populations (8.4) , Clinical Studies (14.2) ]: Amoxicillin and Clavulanate Potassium Tablets: adults and pediatric patients weighing greater than or equal to 40 kg 1.8 Limitations of Use Therapy may be initiated before bacteriological results are available when beta-lactamase-producing pathogens are suspected. When results show susceptibility to amoxicillin alone, amoxicillin and clavulanate potassium tablets should not be used. 1.9 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets and other antibacterial drugs, amoxicillin and clavulanate potassium tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.